Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident.

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Artivion (NYSE:AORT) in the last three months. The following table encapsulates their recent ...

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion Data from the trial demonstrate sustained ...

Artivion, Inc., a medical device company specializing in surgical and medical instruments, reported today that it had identified and begun responding to a cybersecurity incident on November 21, 2024.

Needham analyst Michael Matson has reiterated their bullish stance on AORT stock, giving a Buy rating yesterday. Michael Matson’s rating is based on several favorable developments for Artivion.